Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07304011) titled 'Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent' on Dec. 23, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of California, Davis
Condition:
Acute Myeloid Leukemia
Intervention:
Drug: Azacitidine
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: January 17, 2026
Target Sample Size: 28 ...